Injections in shoulder for patients with long term shoulder pain

To compare efficacy of Glenohumeral with subacromial injections in patient with chronic shoulder pain - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062902

Enrollment

Registered

2024-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Glenohumeral Joint: Single Injection of 9 ml of 0.5% Bupivacaine and 1 ml (40 mg) Triamcinolone acetonide intraarticularly in glenohumeral joint to be injected within 5 minutes Control

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients of 20-70 years of age of either sex coming to pain clinic suffering from chronic shoulder pain.

Exclusion criteria

Exclusion criteria: Patients with known contraindication for block interventions (e. g. infection at site of block, coagulopathy etc), history of adverse reaction to steroids or bupivacaine, uncontrolled Diabetes mellitus and patients suffering from rotator cuff injuries, fracture shoulder joint

Design outcomes

Primary

Measure	Time frame
Following parameters will be recorded to determine effectiveness: - Pain - Range of motion Timepoint: 30 Minutes 1 week 4 weeks	—

Secondary

Measure	Time frame
SPADI ( Shoulder Pain And Disability Score)Timepoint: 30 Minutes 1 week 4 weeks	—

Countries

India

Contacts

Public ContactDr Ashish Verma

PGIMS Rohtak

verma.mbbs@gmail.com8295444434

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026